Log in

Relevant bibliographies by topics / Neurotrophic drugs / Journal articles

To see the other types of publications on this topic, follow the link: Neurotrophic drugs.

Journal articles on the topic 'Neurotrophic drugs'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Neurotrophic drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gupta, Akash, Jeremias G. Galletti, Zhiyuan Yu, Kevin Burgess, and Cintia S. de Paiva. "A, B, C’s of Trk Receptors and Their Ligands in Ocular Repair." International Journal of Molecular Sciences 23, no. 22 (2022): 14069. http://dx.doi.org/10.3390/ijms232214069.

Full text

Abstract:

Neurotrophins are a family of closely related secreted proteins that promote differentiation, development, and survival of neurons, which include nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4. All neurotrophins signal through tropomyosin receptor kinases (TrkA, TrkB, and TrkC) which are more selective to NGF, brain-derived neurotrophic factor, and neurotrophin-3, respectively. NGF is the most studied neurotrophin in the ocular surface and a human recombinant NGF has reached clinics, having been approved to treat neurotrophic keratitis. Brain-d

APA, Harvard, Vancouver, ISO, and other styles

2

Hassan, Khadija, Blondelle Matio Kemkuignou, Marco Kirchenwitz, et al. "Neurotrophic and Immunomodulatory Lanostane Triterpenoids from Wood-Inhabiting Basidiomycota." International Journal of Molecular Sciences 23, no. 21 (2022): 13593. http://dx.doi.org/10.3390/ijms232113593.

Full text

Abstract:

Neurotrophins such as nerve growth factor (ngf) and brain-derived neurotrophic factor (bdnf) play important roles in the central nervous system. They are potential therapeutic drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. In this study, we investigated the neurotrophic properties of triterpenes isolated from fruiting bodies of Laetiporus sulphureus and a mycelial culture of Antrodia sp. MUCL 56049. The structures of the isolated compounds were elucidated based on nuclear magnetic resonance (NMR) spectroscopy in combination with hi

APA, Harvard, Vancouver, ISO, and other styles

3

Khadija, Hassan, Matio Kemkuignou Blondelle, Kirchenwitz Marco, et al. "Neurotrophic and Immunomodulatory Lanostane Triterpenoids from Wood-Inhabiting Basidiomycota." Int. J. Mol. Sci. 23 (March 26, 2023): 13593. https://doi.org/10.3390/ ijms232113593.

Full text

Abstract:

Neurotrophins such as nerve growth factor (ngf) and brain-derived neurotrophic factor (bdnf) play important roles in the central nervous system. They are potential therapeutic drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. In this study, we investigated the neurotrophic properties of triterpenes isolated from fruiting bodies of Laetiporus sulphureus and a mycelial culture of Antrodia sp. MUCL 56049. The structures of the isolated compounds were elucidated based on nuclear magnetic resonance (NMR) spectroscopy in combina

APA, Harvard, Vancouver, ISO, and other styles

4

CASTREN, E. "Neurotrophic effects of antidepressant drugs." Current Opinion in Pharmacology 4, no. 1 (2004): 58–64. http://dx.doi.org/10.1016/j.coph.2003.10.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chaldakov, George N., Luigi Aloe, Stanislav G. Yanev, et al. "Trackins (Trk-Targeting Drugs): A Novel Therapy for Different Diseases." Pharmaceuticals 17, no. 7 (2024): 961. http://dx.doi.org/10.3390/ph17070961.

Full text

Abstract:

Many routes may lead to the transition from a healthy to a diseased phenotype. However, there are not so many routes to travel in the opposite direction; that is, therapy for different diseases. The following pressing question thus remains: what are the pathogenic routes and how can be they counteracted for therapeutic purposes? Human cells contain >500 protein kinases and nearly 200 protein phosphatases, acting on thousands of proteins, including cell growth factors. We herein discuss neurotrophins with pathogenic or metabotrophic abilities, particularly brain-derived neurotrophic factor (

APA, Harvard, Vancouver, ISO, and other styles

6

Baazaoui, Narjes, and Khalid Iqbal. "Alzheimer’s Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound." Biomolecules 12, no. 10 (2022): 1409. http://dx.doi.org/10.3390/biom12101409.

Full text

Abstract:

Alzheimer’s disease (AD) is a progressive neurodegenerative disease with an insidious onset and multifactorial nature. A deficit in neurogenesis and synaptic plasticity are considered the early pathological features associated with neurofibrillary tau and amyloid β pathologies andneuroinflammation. The imbalance of neurotrophic factors with an increase in FGF-2 level and a decrease in brain derived neurotrophic factor (BDNF) and neurotrophin 4 (NT-4) in the hippocampus, frontal cortex and parietal cortex and disruption of the brain micro-environment are other characteristics of AD. Neurotrophi

APA, Harvard, Vancouver, ISO, and other styles

7

Gören, Jessica L. "Brain-derived neurotrophic factor and schizophrenia." Mental Health Clinician 6, no. 6 (2016): 285–88. http://dx.doi.org/10.9740/mhc.2016.11.285.

Full text

Abstract:

Abstract Schizophrenia is a severe disorder affecting approximately 1% of the population. Historically, alterations of dopaminergic function were considered the primary cause of schizophrenia. However, for many patients, drugs that alter dopaminergic function do not consistently lead to resolution of the symptoms of schizophrenia. Thus, there is an increased interest in pathophysiologic processes that result in altered neurodevelopment and plasticity associated with schizophrenia. Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in neurogenesis, synaptic plasticity, cognitio

APA, Harvard, Vancouver, ISO, and other styles

8

Mosiołek, Anna, Jadwiga Mosiołek, Sławomir Jakima, Aleksandra Pięta, and Agata Szulc. "Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD)." Journal of Clinical Medicine 10, no. 15 (2021): 3377. http://dx.doi.org/10.3390/jcm10153377.

Full text

Abstract:

Major depressive disorder (MDD) remains the subject of ongoing research as a multifactorial disease and a serious public health problem. There is a growing body of literature focusing on the role of neurotrophic factors in pathophysiology of MDD. A neurotrophic hypothesis of depression proposes that abnormalities of neurotrophins serum levels lead to neuronal atrophy and decreased neurogenesis, resulting in mood disorders. Consequently, in accordance with recent findings, antidepressant treatment modifies the serum levels of neurotrophins and thus leads to a clinical improvement of MDD. The pu

APA, Harvard, Vancouver, ISO, and other styles

9

Borowicz-Reutt, Kinga K. "How Antidepressant Drugs Affect the Antielectroshock Action of Antiseizure Drugs in Mice: A Critical Review." International Journal of Molecular Sciences 22, no. 5 (2021): 2521. http://dx.doi.org/10.3390/ijms22052521.

Full text

Abstract:

Depression coexists with epilepsy, worsening its course. Treatment of the two diseases enables the possibility of interactions between antidepressant and antiepileptic drugs. The aim of this review was to analyze such interactions in one animal seizure model—the maximal electroshock (MES) in mice. Although numerous antidepressants showed an anticonvulsant action, mianserin exhibited a proconvulsant effect against electroconvulsions. In most cases, antidepressants potentiated or remained ineffective in relation to the antielectroshock action of classical antiepileptic drugs. However, mianserin

APA, Harvard, Vancouver, ISO, and other styles

10

Potupchik, T. V., O. F. Veselova, and I. V. Gatskikh. "Pharmacotherapeutic aspects of nootropics use in people with alcohol dependence." Medical alphabet 2, no. 19 (2019): 37–41. http://dx.doi.org/10.33667/2078-5631-2019-2-19(394)-37-41.

Full text

Abstract:

In the pharmacotherapy of chronic alcoholism a significant place is given to nootropic drugs. Currently, neurodegenerative processes are associated with the activity of various neurotrophic factors of the brain and neuropeptides. An important advantage of the use of neuropeptide drugs (cerebrolysin, semax, cortexin) in the treatment of chronic alcoholism is that they have an organ-specific multimodal effect on the brain: provide metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity. They are recommended for relief of acute withdrawal syndrome, as well as i

APA, Harvard, Vancouver, ISO, and other styles

11

Stepanichev, Mikhail, Nikolay N. Dygalo, Grigory Grigoryan, Galina T. Shishkina, and Natalia Gulyaeva. "Rodent Models of Depression: Neurotrophic and Neuroinflammatory Biomarkers." BioMed Research International 2014 (2014): 1–20. http://dx.doi.org/10.1155/2014/932757.

Full text

Abstract:

Rodent models are an indispensable tool for studying etiology and progress of depression. Since interrelated systems of neurotrophic factors and cytokines comprise major regulatory mechanisms controlling normal brain plasticity, impairments of these systems form the basis for development of cerebral pathologies, including mental diseases. The present review focuses on the numerous experimental rodent models of depression induced by different stress factors (exteroceptive and interoceptive) during early life (including prenatal period) or adulthood, giving emphasis to the data on the changes of

APA, Harvard, Vancouver, ISO, and other styles

12

Uddin, Md Sahab, Abdullah Al Mamun, Md Motiar Rahman, et al. "Natural Products for Neurodegeneration: Regulating Neurotrophic Signals." Oxidative Medicine and Cellular Longevity 2021 (June 21, 2021): 1–17. http://dx.doi.org/10.1155/2021/8820406.

Full text

Abstract:

Neurodegenerative disorders (NDs) are heterogeneous groups of ailments typically characterized by progressive damage of the nervous system. Several drugs are used to treat NDs but they have only symptomatic benefits with various side effects. Numerous researches have been performed to prove the advantages of phytochemicals for the treatment of NDs. Furthermore, phytochemicals such as polyphenols might play a pivotal role in rescue from neurodegeneration due to their various effects as anti-inflammatory, antioxidative, and antiamyloidogenic agents by controlling apoptotic factors, neurotrophic

APA, Harvard, Vancouver, ISO, and other styles

13

Gromova, O. A., I. Yu Torshin, L. V. Stakhovskaia, L. A. Maiorova, and K. S. Ostrenko. "Comparative studies of neurotrophic drugs based on brain hydrolysates." Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119, no. 10 (2019): 134. http://dx.doi.org/10.17116/jnevro2019119101134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

OBARA, Yutaro. "Development of Anti-dementia Drugs Related to Neurotrophic Factors." YAKUGAKU ZASSHI 126, no. 9 (2006): 747–55. http://dx.doi.org/10.1248/yakushi.126.747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Carvey, Paul M., Louis R. Ptak, Donghui Lin, et al. "Alterations in striatal neurotrophic activity induced by dopaminergic drugs." Pharmacology Biochemistry and Behavior 46, no. 1 (1993): 195–204. http://dx.doi.org/10.1016/0091-3057(93)90340-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Mucci, Federico, Alessandro Arone, Riccardo Gurrieri, Francesco Weiss, Gerardo Russomanno, and Donatella Marazziti. "Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism." Life 15, no. 3 (2025): 391. https://doi.org/10.3390/life15030391.

Full text

Abstract:

Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)—such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone—has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. This review attempts to carefully ex

APA, Harvard, Vancouver, ISO, and other styles

17

Petereit, H. F., H. Lindemann, and S. Schoppe. "Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor." Multiple Sclerosis Journal 9, no. 1 (2003): 16–20. http://dx.doi.org/10.1191/1352458503ms869oa.

Full text

Abstract:

Multiple sclerosis (MS), a disease of presumably autoimmune aetiology, is character ized by inflammation, demyelination and axonal degeneratio n in the central nervous system. C urrent treatment concepts target the inflammatory activity, reducing the number of relapses and inflammatory lesions on magnetic resonance imaging as well as the proinflammatory cytokine production in blood lymphocytes. Recently, the neuroprotective aspect of inflammation has been documented and is thought to be mediated by neurotrophins, like brain-derived neurotrophic factor (BDNF). The question whether the in vitro

APA, Harvard, Vancouver, ISO, and other styles

18

Schneider, Andrew, Adam T. Sari, Hasan Alhaddad, and Youssef Sari. "Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson’s Disease." CNS & Neurological Disorders - Drug Targets 19, no. 3 (2020): 195–206. http://dx.doi.org/10.2174/1871527319666200525011110.

Full text

Abstract:

Parkinson’s Disease (PD) is a neurodegenerative disease involving degeneration of dopaminergic neurons of the nigrostriatal pathways. Over the past decades, most of the medications for the treatment of PD patients have been used to modulate dopamine concentrations in the basal ganglia. This includes levodopa and its inhibitory metabolizing enzymes. In addition to modulating dopamine concentrations in the brain, there are D2-like dopamine receptor agonists that mimic the action of dopamine to compensate for the deficit in dopamine found in PD patients. Muscarinic antagonists’ drugs are used rar

APA, Harvard, Vancouver, ISO, and other styles

19

Durany, Nuria, and Johannes Thome. "Neurotrophic factors and the pathophysiology of schizophrenic psychoses." European Psychiatry 19, no. 6 (2004): 326–37. http://dx.doi.org/10.1016/j.eurpsy.2004.06.020.

Full text

Abstract:

AbstractThe aim of this review is to summarize the present state of findings on altered neurotrophic factor levels in schizophrenic psychoses, on variations in genes coding for neurotrophic factors, and on the effect of antipsychotic drugs on the expression level of neurotrophic factors. This is a conceptual paper that aims to establish the link between the neuromaldevelopment theory of schizophrenia and neurotrophic factors. An extensive literature review has been done using the Pub Med database, a service of the National Library of Medicine, which includes over 14 million citations for biome

APA, Harvard, Vancouver, ISO, and other styles

20

Jain, Nidhi, Shailesh Yadav, Manoj Goyal, Kiran Kumar Singal, Parveen Gupta, and Monika Bansal. "Cerebroprotein Hydrolysate: Innovation in Neurodegenerative Disorders." International Journal of Medical and Dental Sciences 3, no. 1 (2014): 382. http://dx.doi.org/10.19056/ijmdsjssmes/2014/v3i1/80742.

Full text

Abstract:

Stroke, traumatic brain injury and neurodegenerative disorders are one of the leading causes of death and disability in both developing and developed countries. A number of drugs including neurotrophic drugs are available for these disorders. Cerebroprotein hydrolysate is the latest one offering new hopes to patients suffering from these disorders. Its superiority is because of different actions which help in faster and more complete nerve repair and growth than other neurotrophic agents. It acts by multiple mechanisms viz. regulation and improvement of the neuronal metabolism, modulation of t

APA, Harvard, Vancouver, ISO, and other styles

21

Gavrilova, S. I., and T. P. Safarova. "Neurotrophins and Neurotrophic Therapy (Based on the Cerebrolysin Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 1." Psikhiatriya 19, no. 2 (2021): 87–103. http://dx.doi.org/10.30629/2618-6667-2021-19-2-87-103.

Full text

Abstract:

Background: Alzheimer’s disease (AD) is the most common neurocognitive disorder and a global health problem. The prevalence of AD is increasing dramatically, and will double in two decades to reach 100 million cases worldwide. Therefore, the development of disease-modifying therapies that can delay or even prevent the onset and progression of AD has become a global priority.Objective: to present a review of domestic and foreign modern studies covering the pathogenesis of AD and disease-modifying therapy.Material and methods: the keywords “Alzheimer’s disease, late age, mild cognitive impairmen

APA, Harvard, Vancouver, ISO, and other styles

22

Vernygorodsky, V. S., M. V. Vlasenko, and N. M. Fetisova. "NEUROVITAN IN COMPLEX TREATMENT AND REHABILITATION PATIENTS WITH HYPOTHYROIDISM." Problems of Endocrine Pathology 36, no. 2 (2011): 36–40. http://dx.doi.org/10.21856/j-pep.2011.2.06.

Full text

Abstract:

Clinical efficacy of the drug Neurovitan in the complex treatment of hypothyroidism was studied ulcerative polyneuropathies. It has been shown that for faster recovery of impaired pa it is genetically determined to prescribe drugs that have neurotrophic effects, in particular Neurovitan.

APA, Harvard, Vancouver, ISO, and other styles

23

Abolhasanpour, Nasrin, Poorya Sadeghi, Mohammad Gholizadeh, Hanieh Salehi-Pourmehr, and Leila Hosseini. "Cerebrolysin Use in Stroke and Spinal Cord Injury: Review of the Literature and Outcomes." International Journal of Drug Research in Clinics 1 (January 1, 2023): e22. http://dx.doi.org/10.34172/ijdrc.2023.e22.

Full text

Abstract:

Cerebrolysin (CBL) is a porcine brain-derived preparation with noticeable neurotrophic and neuroprotective activity. Treatment with CBL has significant potential to treat various debilitating neurological diseases such as traumatic brain injuries, ischemic stroke, and spinal cord injury. Although using CBL is not approved in the United States, about 50 countries have used it in clinics. CBL is a drug similar to neurotrophins with a multimodal action that effectively helps the central nervous system (CNS) and brain function properly through the protection, maintenance, and regeneration of the n

APA, Harvard, Vancouver, ISO, and other styles

24

Hughes, RA, and PD O'Leary. "NEUROTROPHIC FACTORS AND THE DEVELOPMENT OF DRUGS TO PROMOTE MOTONEURON SURVIVAL." Clinical and Experimental Pharmacology and Physiology 23, no. 10-11 (1996): 965–69. http://dx.doi.org/10.1111/j.1440-1681.1996.tb01150.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hassanzadeh, Parichehr. "The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs." Biomedical Reviews 21 (December 31, 2010): 31. http://dx.doi.org/10.14748/bmr.v21.45.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Mudo, G., N. Belluardo, and K. Fuxe. "Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms." Journal of Neural Transmission 114, no. 1 (2006): 135–47. http://dx.doi.org/10.1007/s00702-006-0561-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Kornhuber, Johannes, and Erich Gulbins. "New Molecular Targets for Antidepressant Drugs." Pharmaceuticals 14, no. 9 (2021): 894. http://dx.doi.org/10.3390/ph14090894.

Full text

Abstract:

Major depressive disorder (MDD) is a common and severe mental disorder that is usually recurrent and has a high risk of suicide. This disorder manifests not only with psychological symptoms but also multiple changes throughout the body, including increased risks of obesity, diabetes, and cardiovascular disease. Peripheral markers of oxidative stress and inflammation are elevated. MDD is therefore best described as a multisystem whole-body disease. Pharmacological treatment with antidepressants usually requires several weeks before the desired effects manifest. Previous theories of depression,

APA, Harvard, Vancouver, ISO, and other styles

28

Sarabi, Matthieu, Aurélie Perraud, Clément Mazouffre, Michelle Nouaille, Marie-Odile Jauberteau, and Muriel Mathonnet. "Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients." Biomedical Reports 6, no. 1 (2016): 89–94. http://dx.doi.org/10.3892/br.2016.801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Torshin, I. Yu, O. A. Gromova, L. V. Stakhovskaya, V. A. Semenov, and I. A. Shchukin. "Chemotranscriptome analysis indicates the neurotrophic and neuromodulator effects of a citicoline molecule." Neurology, Neuropsychiatry, Psychosomatics 12, no. 4 (2020): 91–99. http://dx.doi.org/10.14412/2074-2711-2020-4-91-99.

Full text

Abstract:

Objective: to investigate the effect of citicoline (CTC) on gene transcription.Material and methods. Chemotranscriptome analysis of the CTC molecule was carried out on an NPC.TAK model, provided that the cells were incubated with CTC for 24 hours.Results and discussion. CTC dose-dependently affected the transcription of 8,838 out of 12,716 annotated human genes, mainly by increasing the transcription of the genes involved: 1) in the neurotransmitter metabolism of serotonin (n=36), dopamine (n=32), GABA (n=14), and acetylcholine (n=27); 2) in showing the effects of neurotrophic factors (n=152),

APA, Harvard, Vancouver, ISO, and other styles

30

Gudasheva, Tatiana A., Polina Povarnina, Alexey V. Tarasiuk, and Sergey B. Seredenin. "The Low Molecular Weight Brain-derived Neurotrophic Factor Mimetics with Antidepressant-like Activity." Current Pharmaceutical Design 25, no. 6 (2019): 729–37. http://dx.doi.org/10.2174/1381612825666190329122852.

Full text

Abstract:

The search for new highly-effective, fast-acting antidepressant drugs is extremely relevant. Brain derived neurotrophic factor (BDNF) and signaling through its tropomyosin-related tyrosine kinase B (TrkB) receptor, represents one of the most promising therapeutic targets for treating depression. BDNF is a key regulator of neuroplasticity in the hippocampus and the prefrontal cortex, the dysfunction of which is considered to be the main pathophysiological hallmark of this disorder. BDNF itself has no favorable drug-like properties due to poor pharmacokinetics and possible adverse effects. The d

APA, Harvard, Vancouver, ISO, and other styles

31

Fišar, Zdeněk, and J. Hroudová. "Intracellular Signalling Pathways and Mood Disorders." Folia Biologica 56, no. 4 (2010): 135–48. http://dx.doi.org/10.14712/fb2010056040135.

Full text

Abstract:

Findings are summarized about basic intracellular signalling pathways influencing neurotransmission and involved in neurodegenerative or neuropsychiatric disorders. Psychotropic drugs used in the therapy of a series of mental disorders, mood disorders especially, show neurotrophic or neuroprotective effects after long-term treatment. Thus, beyond adenylate cyclase, guanylate cyclase and calcium system, attention has been paid to the tyrosine kinase pathway and Wnt pathway. New neurochemical hypotheses of mood disorders are disclosed; they were formulated on the basis of known effects of antide

APA, Harvard, Vancouver, ISO, and other styles

32

Khramtsov, D. "Dynamics of brain derived neurotrophic factor when using neuromodulation as part of comprehensive rehabilitation after a stroke." Journal of Education, Health and Sport 78 (February 28, 2025): 60156. https://doi.org/10.12775/jehs.2025.78.60156.

Full text

Abstract:

The aim of the study was to assess the dynamics of brain derived neurotrophic factor when using neuromodulation. Material and methods. The study was conducted on the basis of clinical departments of the Medical Institute of the Petro Mohyla Black Sea National University. 140 patients with ischemic stroke were treated. The total sample was randomly divided into 4 clinical groups. Patients in group I (n=30) received standard therapy, which included antithrombotic therapy, antihypertensive drugs, statins, and, according to indications, NSAIDs, antiemetics, insulin and other hypoglycemic drugs, an

APA, Harvard, Vancouver, ISO, and other styles

33

Muraleekrishna, Manu, Ayushi Agarwal, Abhishek Kumar, Narottama Sindhu, and Radhika Tandon. "Neurotrophic keratopathy and keratoconjunctivitis medicamentosa in trigeminal trophic syndrome." Indian Journal of Ophthalmology - Case Reports 5, no. 2 (2025): 256–58. https://doi.org/10.4103/ijo.ijo_2165_24.

Full text

Abstract:

To report a rare case of neurotrophic keratopathy and keratoconjunctivitis medicamentosa associated with trigeminal trophic syndrome (TTS). Observational case report with review of literature. A 55-year-old lady diagnosed to have TTS presented with a nonhealing epithelial defect triggered by use of topical herbal medication. The possibility of underlying neurotrophic keratopathy was considered in differential diagnosis of keratoconjunctivitis medicamentosa. Reduced corneal sensitivity and the morphology of the epithelial defect margins corroborated the diagnosis. The patient responded to treat

APA, Harvard, Vancouver, ISO, and other styles

34

Garrido P., Maritza, and Carmen Romero O. "Receptor TRKB y conexina 43 en cáncer de ovario." Revista Hospital Clínico Universidad de Chile 24, no. 3 (2013): 213–20. http://dx.doi.org/10.5354/2735-7996.2013.73161.

Full text

Abstract:

Ovarian cancer is one of the most aggressive and poor prognosis cancer, which appears predominantly as Epithelial Ovarian Cancer (EOC). Many studies have been conducted to establish connections between neurotrophin receptors and the development, progression and response of cancer therapy. The tyrosine kinases receptors (TRK) have been considered as important target in several cancers, including EOC. Metastasic process and resistance to cancer therapies have been associated with the TRK neurotrophin receptor B (TRKB), whose main ligand is brain derivated neurotrophic ligand (BDNF). Another impo

APA, Harvard, Vancouver, ISO, and other styles

35

Lanshakov, D. A. "Effective Transduction of Brain Neurons with Lentiviral Vectors Purified by Ion-Exchange Chromatography." Biotekhnologiya 36, no. 5 (2020): 89–97. http://dx.doi.org/10.21519/0234-2758-2020-36-5-89-97.

Full text

Abstract:

The development of methods for purification viral vectors for gene therapy is one of the most important and urgent problems of modern biology and medicine. Recently, drugs that carry cerebral neurotrophic factors, such as BDNF, have become increasingly popular. However, viral drugs for gene therapy should meet certain requirements, including high titer and applicability for in vivo studies. At the same time, the creation of such vectors requires cost-effective, inexpensive and affordable methods for standard laboratories. This study compares various methods for purification of lentiviral vecto

APA, Harvard, Vancouver, ISO, and other styles

36

Стамбольский, Д. В., О. С. Плеханова, И. Ю. Юдина, et al. "The brain-derived neurotrophic factor (BDNF) system as a therapeutical target for development of drugs restoring innervation." ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia», no. 4(61) (December 19, 2017): 142–52. http://dx.doi.org/10.25557/igpp.2017.4.8534.

Full text

Abstract:

Мозговой нейротрофический фактор (BDNF) является одним из основных нейротрофических факторов, участвующих в поддержании функционирования и регенерации нервной системы. В последние годы BDNF рассматривают как многообещающую терапевтическую мишень, на основании полученных данных о том, что BDNF улучшает регенерацию нейронов. Цель обзора - суммировать данные об экспрессии BDNF, его сигнализации, эффектах и механизмах стимуляции реиннервации. Анализ исследований последних десятилетий позволяет сделать заключение о целесообразности и перспективности разработок, направленных на создание лекарственны

APA, Harvard, Vancouver, ISO, and other styles

37

Markov, Dmitrii D., Oleg V. Dolotov, and Igor A. Grivennikov. "The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs." International Journal of Molecular Sciences 24, no. 7 (2023): 6664. http://dx.doi.org/10.3390/ijms24076664.

Full text

Abstract:

Major depression is one of the most prevalent mental disorders, causing significant human suffering and socioeconomic loss. Since conventional antidepressants are not sufficiently effective, there is an urgent need to develop new antidepressant medications. Despite marked advances in the neurobiology of depression, the etiology and pathophysiology of this disease remain poorly understood. Classical and newer hypotheses of depression suggest that an imbalance of brain monoamines, dysregulation of the hypothalamic-pituitary-adrenal axis (HPAA) and immune system, or impaired hippocampal neurogene

APA, Harvard, Vancouver, ISO, and other styles

38

Lilja, Anna M., Yu Luo, Qian-sheng Yu, et al. "Neurotrophic and Neuroprotective Actions of (−)- and (+)-Phenserine, Candidate Drugs for Alzheimer’s Disease." PLoS ONE 8, no. 1 (2013): e54887. http://dx.doi.org/10.1371/journal.pone.0054887.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Yue, Mengyun, Jing Wei, Wenjie Chen, Daojun Hong, Tingtao Chen, and Xin Fang. "Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis." Nutrients 14, no. 22 (2022): 4886. http://dx.doi.org/10.3390/nu14224886.

Full text

Abstract:

Parkinson’s disease (PD) is a neurodegenerative disease (NDD) with high and ongoing morbidity, bringing heavy burdens to PD patients seriously. Finding neurotrophic drugs still remains vital due to the limited drug spectrum available currently. Substantial evidence suggests that glucagon-like peptide 1 (GLP-1) exerts neuroprotection on PD, yet the short-lived biological activity markedly hindered its application. Herein, we investigated the neurotrophic role of the next-generation probiotic strain L. lactis MG1363-pMG36e-GLP-1 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD m

APA, Harvard, Vancouver, ISO, and other styles

40

Omaka, Andrew U., and Amarachi Ezeigbo. "New Trends in Neuro-protection in Glaucoma." Journal of the Nigerian Optometric Association 26, no. 1 (2024): 48–58. http://dx.doi.org/10.4314/jnoa.v26i1.7.

Full text

Abstract:

Recent advancements in neuroprotection for glaucoma have seen a shift towards multifaceted approaches targeting various aspects of the disease's pathophysiology. Traditional strategies were primarily focused on lowering intraocular pressure (IOP) but emerging trends highlight the importance of preserving retinal ganglion cells (RGCs) and their axons. Novel therapeutics aim to enhance neurotrophic support, reduce excitotoxicity, and mitigate oxidative stress, complementing IOP-lowering therapies for comprehensive management. Stem cell therapies, neurotrophic factors, and gene therapies show pro

APA, Harvard, Vancouver, ISO, and other styles

41

Mathew, Sanjay J., Kathryn Keegan, and Lisa Smith. "Glutamate modulators as novel interventions for mood disorders." Revista Brasileira de Psiquiatria 27, no. 3 (2005): 243–48. http://dx.doi.org/10.1590/s1516-44462005000300016.

Full text

Abstract:

Recent evidence suggests that critical molecules in neurotrophic signaling cascades are long-term targets for currently available monoaminergic antidepressants. As chronic and severe mood disorders are characterized by impairments in neuronal resilience, pharmacological strategies that subserve a neuroprotective function might alter disorder pathophysiology and modify disease progression. Several promising approaches involve modulation of the glutamate neurotransmitter system, via post-synaptic receptor blockade or potentiation and presynaptic vesicular release inhibition. A focused review of

APA, Harvard, Vancouver, ISO, and other styles

42

Luer, Mark S., Denise H. Rhoney, Melody Hughes, and Jimmi Hatton. "New Pharmacologic Strategies for Acute Neuronal Injury." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 16, no. 5 (1996): 830–48. http://dx.doi.org/10.1002/j.1875-9114.1996.tb03000.x.

Full text

Abstract:

The number of new drugs for treating neurotrauma is rapidly expanding. Emerging theories regarding the mechanisms of secondary neuronal injury provide the scientific basis for evaluating these new agents. Some of the most promising mechanisms for intervention are ionotropic channel antagonism, inhibition of lipid peroxidation, and neurotrophic factor augmentation. Many of these new agents are undergoing clinical trials to establish their roles in therapy.

APA, Harvard, Vancouver, ISO, and other styles

43

Fazzari, Maria, Giulia Lunghi, Elena Chiricozzi, Laura Mauri, and Sandro Sonnino. "Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition." Biomedicines 10, no. 2 (2022): 363. http://dx.doi.org/10.3390/biomedicines10020363.

Full text

Abstract:

Gangliosides are glycosphingolipids which are particularly abundant in the plasma membrane of mammalian neurons. The knowledge of their presence in the human brain dates back to the end of 19th century, but their structure was determined much later, in the middle of the 1950s. From this time, neurochemical studies suggested that gangliosides, and particularly GM1 ganglioside, display neurotrophic and neuroprotective properties. The involvement of GM1 in modulating neuronal processes has been studied in detail by in vitro experiments, and the results indicated its direct role in modulating the

APA, Harvard, Vancouver, ISO, and other styles

44

Steiner, Joseph P., Maureen A. Connolly, Heather L. Valentine, et al. "Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A." Nature Medicine 3, no. 4 (1997): 421–28. http://dx.doi.org/10.1038/nm0497-421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jessica, Ciesler, and Youssef Sari. "Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer’s disease." Open Journal of Neuroscinece 3, no. 1 (2013): 1. http://dx.doi.org/10.13055/ojns_3_1_2.130408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Hemant, S. Kanhere, C. Bansinge Pallavi, J. Helen Ratna Monica, and K. Rathod Sawan. "Targeting Brain-Derived Neurotrophic Factor (BDNF) - An Important Strategy to Alzheimer's Disease." Journal of Pharmaceutical and Medicinal Research 6, no. 1 (2021): 121–27. http://dx.doi.org/10.30799/jpmr.055.21060103.

Full text

Abstract:

Many theories have been proposed to explain why candidate disease-modifying drugs (DMTs) for Alzheimer's disease (AD) failed. Late initiation of treatments during AD development, inappropriate drug dosages, incorrect selection of main therapeutic targets, and primarily inadequate understanding of the complex pathophysiology of AD are the most prominent ones. Reduced expression of Brain Derived Neurotrophic Factor (BDNF) is essential in the pathogenesis of Alzheimer's disease. BDNF plays important functions in cell survival and differentiation, neuronal outgrowth and plasticity. It can be a nov

APA, Harvard, Vancouver, ISO, and other styles

47

Pardossi, Simone, Andrea Fagiolini, and Alessandro Cuomo. "Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review." International Journal of Molecular Sciences 25, no. 23 (2024): 13098. https://doi.org/10.3390/ijms252313098.

Full text

Abstract:

Brain-derived neurotrophic factor (BDNF) is critical for neuroplasticity, synaptic transmission, and neuronal survival. Studies have implicated it in the pathophysiology of depression, as its expression is significantly reduced in brain areas such as the prefrontal cortex and hippocampus in patients with depression. Our narrative review focuses on the relationship between BDNF, ketamine, and esketamine, specifically by summarizing human studies investigating BDNF variations in patients treated with these two drugs. BDNF plays a pivotal role in neuroplasticity and neurotrophic mechanisms that c

APA, Harvard, Vancouver, ISO, and other styles

48

Maik-Rachline, Galia, and Rony Seger. "Variable phosphorylation states of pigment-epithelium–derived factor differentially regulate its function." Blood 107, no. 7 (2006): 2745–52. http://dx.doi.org/10.1182/blood-2005-06-2547.

Full text

Abstract:

AbstractThe pigment epithelium–derived factor (PEDF) belongs to the family of noninhibitory serpins. Although originally identified in the eye, PEDF is widely expressed in other body regions including the plasma. This factor can act either as a neurotrophic or as an antiangiogenic factor, and we previously showed that the 2 effects of PEDF are regulated through phosphorylation by PKA and CK2. Here, we studied the interplay between the PKA and CK2 phosphorylation of PEDF, and found that a PEDF mutant mimicking the CK2-phosphorylated PEDF cannot be phosphorylated by PKA, while the mutant mimicki

APA, Harvard, Vancouver, ISO, and other styles

49

Mosiołek, Anna, Aleksandra Pięta, Sławomir Jakima, Natalia Zborowska, Jadwiga Mosiołek, and Agata Szulc. "Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)." Journal of Clinical Medicine 10, no. 8 (2021): 1706. http://dx.doi.org/10.3390/jcm10081706.

Full text

Abstract:

Major depressive disorder (MDD) is one of the most prevalent mental illness and a leading cause of disability worldwide. Despite a range of effective treatments, more than 30% of patients do not achieve remission as a result of conventional therapy. In these circumstances the identification of novel drug targets and pathogenic factors becomes essential for selecting more efficacious and personalized treatment. Increasing evidence has implicated the role of inflammation in the pathophysiology of depression, revealing potential new pathways and treatment options. Moreover, convergent evidence in

APA, Harvard, Vancouver, ISO, and other styles

50

Gaybiev, Akmaljon Axmadjonovich, and Aziza Takhirovna Djurabekova. "CHANGES IN NEUROTROPHIC FACTOR IN CHILDREN AND ADOLESCENTS WITH DIABETIC POLYNEUROPATHY DURING THERAPY." Journal of neurology and neurosurgical research 3, no. 3 (2022): 6–10. https://doi.org/10.5281/zenodo.6759381.

Full text

Abstract:

The absence of clear clinical signs of diabetic polyneuropathy in children and adolescents, the asymptomatic progression of the process, compared with the adult population, is of great interest among physicians dealing with this problem. In the work of the study, laboratory indicators of ciliary and brain-derived neurotrophic factor were used as a prognostic marker, before and after treatment, with drugs proposed as an additional therapy to the main traditional treatment. The results of the study showed the effectiveness of the use of diagnostic and treatment methods.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!